Lung cancer drug levels under the microscope
NCT ID NCT04557007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study looked at how much of the immunotherapy drug pembrolizumab stays in the blood of patients with advanced non-small cell lung cancer. Researchers measured drug levels and immune responses in 80 patients receiving pembrolizumab alone or with chemotherapy. The goal was to see if drug concentration relates to how well the cancer responds or to side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab
- What this could lead to
- If successful, this study could help doctors personalize pembrolizumab dosing for lung cancer patients, potentially improving outcomes and reducing side effects.
- What could go wrong
- This is an observational study, not a treatment trial. It was terminated early, so results may be limited and not conclusive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St Olavs University Hospital
Trondheim, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?